Novo Nordisk cuts jobs at key U.S. manufacturing site for Wegovy - report
NegativeFinancial Markets

Novo Nordisk is reportedly cutting jobs at its key U.S. manufacturing site for Wegovy, a weight-loss drug that has gained significant attention. This move raises concerns about the company's future production capabilities and the potential impact on patients relying on this medication. As Wegovy continues to be a crucial player in the obesity treatment market, these job cuts could affect not only the workforce but also the availability of this important drug.
— Curated by the World Pulse Now AI Editorial System